US Stock MarketDetailed Quotes
TSHA Taysha Gene Therapies
- 2.5800
- +0.1600+6.61%
Close May 2 16:00 ET
- 2.5800
- 0.00000.00%
Post 16:00 ET
482.51MMarket Cap-2687P/E (TTM)
2.6400High2.4100Low1.49MVolume2.4900Open2.4200Pre Close3.77MTurnover1.49%Turnover RatioLossP/E (Static)187.02MShares3.890052wk High6.43P/B258.27MFloat Cap0.500052wk Low--Dividend TTM100.10MShs Float33.3500Historical High--Div YieldTTM9.50%Amplitude0.5000Historical Low2.5280Avg Price1Lot Size
Taysha Gene Therapies Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 17.39%-73.02M | -209.55%-16.12M | 37.70%-17.95M | 43.73%-18.77M | 50.69%-20.19M | 24.48%-88.39M | 136.54%14.71M | 9.78%-28.81M | -46.18%-33.35M | -85.79%-40.94M |
| Net income from continuing operations | 32.80%-111.57M | 186.68%47.74M | -341.39%-117.09M | 27.85%-24.6M | 64.98%-17.62M | 4.88%-166.01M | -9.31%-55.08M | 48.18%-26.53M | 16.70%-34.09M | -57.12%-50.32M |
| Operating gains losses | --36.95M | ---63.51M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Depreciation and amortization | 16.98%1.37M | 1.10%366K | 19.49%331K | 25.64%343K | 27.31%331K | 138.21%1.17M | 73.21%362K | 66.87%277K | 221.18%273K | 712.50%260K |
| Other non cash items | 167.01%9.27M | 198.26%1.71M | 399.35%3.07M | 666.42%4.06M | -75.58%428K | -65.76%3.47M | -80.46%574K | -59.23%614K | 173.20%530K | -68.13%1.75M |
| Change In working capital | -197.27%-18.01M | -117.11%-4.85M | 3.57%-7.37M | 81.07%-796K | -345.43%-5M | -35.40%18.52M | 1,298.37%28.33M | -161.17%-7.64M | -131.66%-4.21M | 135.92%2.04M |
| -Change in prepaid assets | 187.88%6.01M | 1,754.63%2M | 84.16%3.5M | 575.92%909K | -247.60%-400K | 162.12%2.09M | 105.90%108K | 8.45%1.9M | -121.18%-191K | 106.48%271K |
| -Change in payables and accrued expense | 49.95%-8.57M | 39.13%-3.25M | 35.83%-6.12M | 117.19%690K | -93.82%109K | -153.48%-17.13M | -238.29%-5.33M | -188.83%-9.54M | -132.42%-4.01M | -65.03%1.77M |
| -Change in other working capital | -146.04%-15.45M | ---3.6M | ---4.75M | ---2.4M | ---4.71M | --33.56M | ---- | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 17.39%-73.02M | -209.55%-16.12M | 37.70%-17.95M | 43.73%-18.77M | 50.69%-20.19M | 24.48%-88.39M | 136.54%14.71M | 9.78%-28.81M | -46.18%-33.35M | -85.79%-40.94M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 70.51%-7.35M | 99.58%-10K | -15.56%-3.49M | 100.59%48K | 65.87%-3.9M | -15.66%-24.93M | 72.18%-2.37M | 24.54%-3.02M | 4.53%-8.11M | -2,039.89%-11.43M |
| Net PPE purchase and sale | 81.24%-3.87M | 99.26%-17K | --0 | 100.61%48K | 53.72%-3.9M | -34.73%-20.62M | 72.08%-2.31M | 42.32%-2.02M | -162.27%-7.86M | -1,478.09%-8.43M |
| Net intangibles purchase and sale | 17.65%-3.5M | --0 | -250.00%-3.5M | --0 | --0 | 32.00%-4.25M | --0 | -100.00%-1M | 95.45%-250K | ---3M |
| Net other investing changes | 127.87%17K | --7K | ---- | ---- | ---- | ---61K | ---- | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 70.51%-7.35M | 99.58%-10K | -15.56%-3.49M | 100.59%48K | 65.87%-3.9M | -15.66%-24.93M | 72.18%-2.37M | 24.54%-3.02M | 4.53%-8.11M | -2,039.89%-11.43M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 161.81%136.39M | -110.30%-4.25M | 136,637.86%140.63M | -96.60%377K | -245.79%-370K | 33.30%52.1M | 352.85%41.23M | -100.34%-103K | 11.08M | -107K |
| Net issuance payments of debt | ---3.45M | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Net common stock issuance | 164.42%140.79M | -101.02%-423K | --140.71M | ---- | ---- | --53.24M | --41.6M | --0 | ---- | ---- |
| Proceeds from stock option exercised by employees | -73.12%68K | --0 | 126.47%18K | --0 | -81.95%50K | --253K | --0 | ---68K | --44K | --277K |
| Net other financing activities | 27.50%-1.02M | -0.81%-375K | -177.14%-97K | 79.80%-123K | -9.38%-420K | -60.18%-1.4M | ---372K | ---35K | ---609K | ---384K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 161.81%136.39M | -110.30%-4.25M | 136,637.86%140.63M | -96.60%377K | -245.79%-370K | 33.30%52.1M | 352.85%41.23M | -100.34%-103K | --11.08M | ---107K |
| Net cash flow | ||||||||||
| Beginning cash position | -40.35%90.52M | 351.82%166.92M | -30.72%47.72M | -33.45%66.06M | -40.35%90.52M | -39.61%151.74M | -80.70%36.94M | -65.10%68.88M | -56.59%99.27M | -39.61%151.74M |
| Current changes in cash | 191.51%56.02M | -138.03%-20.38M | 473.27%119.2M | 39.65%-18.34M | 53.40%-24.46M | 38.48%-61.22M | 235.04%53.57M | -436.06%-31.93M | 2.95%-30.39M | -132.50%-52.47M |
| End cash Position | 61.89%146.54M | 61.89%146.54M | 351.82%166.92M | -30.72%47.72M | -33.45%66.06M | -40.35%90.52M | -40.35%90.52M | -80.70%36.94M | -65.10%68.88M | -56.59%99.27M |
| Free cash flow | 29.02%-80.39M | -230.08%-16.13M | 32.61%-21.45M | 54.86%-18.72M | 54.01%-24.09M | 18.28%-113.26M | 125.43%12.4M | 11.42%-31.83M | -32.42%-41.47M | -132.03%-52.37M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg